Spero Therapeutics Accounts Payable

Spero Therapeutics (SPRO) currently reports a accounts payable of $220K as of March 2026. That compares with $1.8M in the prior-year period — down 87.7% year over year. Use the charts on this page to explore Spero Therapeutics's accounts payable history and peer comparisons.

Spero Therapeutics's accounts payable decreased from $1.8M to $220K — a 87.7% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Spero Therapeutics reported $220K in accounts payable as of March 2026. That compares with $1.8M in the prior-year period — down 87.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $220K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Spero Therapeutics, and consider following SPRO for alerts when major investors trade the stock.

Spero Therapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $220K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SPRO with unrelated industries.